GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Buyback Yield %

BioVaxys Technology (BioVaxys Technology) Buyback Yield % : -8.61 (As of Jun. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BioVaxys Technology's current buyback yield was -8.61%.


BioVaxys Technology Buyback Yield % Historical Data

The historical data trend for BioVaxys Technology's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Buyback Yield % Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
Buyback Yield %
- -29.21 -9.71 -8.90 -4.88

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -8.35 -44.77 -

Competitive Comparison of BioVaxys Technology's Buyback Yield %

For the Biotechnology subindustry, BioVaxys Technology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Buyback Yield % falls into.



BioVaxys Technology Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BioVaxys Technology's Buyback Yield for the fiscal year that ended in Oct. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.809) / 16.5722199
=-4.88%

BioVaxys Technology's annualized Buyback Yield for the quarter that ended in Jul. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 2.2637472
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jul. 2023) data.


BioVaxys Technology Buyback Yield % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (BioVaxys Technology) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.